fbpx

Acceptable Thresholds Committee

The volunteer ELEVATEGENETICS Acceptable Thresholds Committee establishes thresholds for grading the accuracy of clinical genetic and genomic tests. This committee helps fulfill an essential need because many clinical laboratories are running clinical tests that are unverified by any third party, and are too-frequently inaccurate, even when the laboratories are CLIA certified or CAP accredited. Unfortunately, most clinicians, patients, health insurers, and sometimes even the labs themselves are unaware of systematic laboratory failures that too-often lead to inaccurate test results, which can ultimately result in physical as well as financial harm to patients. While different regulatory bodies within the United States focus on different aspects of clinical testing with varying rigor, the nonprofit Center for Genomic Interpretation is the only organization providing test users and payers with a rigorous, unbiased, and systematic way to cross compare the accuracy of competing clinical genetic and genomic tests. The ELEVATEGENETICS Acceptable Thresholds Committee defines the clinically relevant testing “challenges” that participating laboratories will be evaluated against in ELEVATEGENETICS BRILLIANT assessments. The committee also sets the thresholds for accuracy scores by which different types of tests are awarded: Elite, Satisfactory, or Participating grades.

Patient Advocates

Maureen Boesen

Maureen Boesen

BRCA patient; Nipples Optional

Allison Mihalich

Allison Mihalich

NIPT parent

Erika Stallings, J.D.

Erika Stallings, J.D.

Co-Founder of Basser Center for BRCA

Courtney Glass, J.D.

Courtney Glass, J.D.

BRCA patient

Wenora Johnson

Wenora Johnson

Lynch patient; FORCE

Charles Steward, PhD

Charles Steward, PhD

Rare Disease Dad

Manju George, PhD

Manju George, PhD

Rectal cancer survivor

Ricki Lewis, PhD

Ricki Lewis, PhD

Cancer Survivor & Senior Medical Writer

Clinical & Industry Advocates

Jeff Allen, PhD

Jeff Allen, PhD

President & CEO; Friends of Cancer Research

Mark Fleury, PhD

Mark Fleury, PhD

Policy Development, Emerging Science; American Cancer Society

Nirupama Shridhar, PhD, MPH

Nirupama Shridhar, PhD, MPH

State Genetics Coordinator, Washington State Department of Health

Ranjit Goudar, MD

Ranjit Goudar, MD

Hereditary Cancer Clinic Director; Virginia Oncology Associates

David Seidenwurm, MD

David Seidenwurm, MD

CMO Sutter Medical Foundation- Quality, Value Based Pymts & Safety

Suresh Mukherji, MD, MBA, FACR

Suresh Mukherji, MD, MBA, FACR

National Alliance of Health Care Purchasers Coalition

Lee Ellis, MD

Lee Ellis, MD

UT MD Anderson Cancer Ctr, ASCO

Robert Cook-Deegan, MD

Robert Cook-Deegan, MD

Founded Duke Center for Genome Ethics, Law and Policy

Gabriela Portugal, MD

Gabriela Portugal, MD

Director of Cancer Program and Latina Cancer Survivor Advocate

Alexander Lazar, MD, PhD

Alexander Lazar, MD, PhD

Professor of Pathology & Genomic Medicine, MD Anderson

Kevin Knopf, MD, MPH

Kevin Knopf, MD, MPH

Chief of Hem/Onc & UCSF Professor on Health Economics

Michael J Sinosich, BSc AIMLS PhD FFScRCPA

Michael J Sinosich, BSc AIMLS PhD FFScRCPA

(Australia) Scientific Director and Manager Prenatal Testing, DHM Pathology Sonic Healthcare Ltd

Heather E. Williams, PhD, MS, PgD, ErCLG, CG(ASCP)MB

Heather E. Williams, PhD, MS, PgD, ErCLG, CG(ASCP)MB

Kim Skellington, CGC

Kim Skellington, CGC

Observing Members

Daniel Edelman, PhD FDA

Daniel Edelman, PhD FDA

Biologist, Personalized Medicine

Thierry Vilboux, PhD FDA

Thierry Vilboux, PhD FDA

Senior Staff Fellow, Personalized Medicine

John Pfeifer, MD PhD

John Pfeifer, MD PhD

Professor, Washington University